This text examines the methods needed to analyze new adverse drug reactions, both inside and outside pharmaceutical companies. It evaluates the drug information cycle within pharmaceutical companies, which incorporates feedback about the drug from clinical trials (pre-marketing), epidemiological studies (pre- and post-marketing), and adverse event feedback (from doctors and drug information centres), an ongoing process known as "Pharmacovigilance". The information is then analyzed and collated prior to feeding the results back into the medical community and the drug development cycle. The book assesses existing methods of collection, storage and processing of adverse event data, and outlines ways of improving the drug information cycle. The fourth edition contains new chapters on: legal aspects; statistical methods; pharmacoepidemiology; quality of life; pharmacovigilance centres; mechanisms of ADRs; interactions and pharmacogenetics; and causality and signal recognition.
"synopsis" may belong to another edition of this title.
Seller: Ammareal, Morangis, France
Hardcover. Condition: Très bon. Ancien livre de bibliothèque avec équipements. Couverture différente. Edition 1998. Ammareal reverse jusqu'à 15% du prix net de cet article à des organisations caritatives. ENGLISH DESCRIPTION Book Condition: Used, Very good. Former library book. Different cover. Edition 1998. Ammareal gives back up to 15% of this item's net price to charity organizations. Seller Inventory # F-979-663
Seller: NEPO UG, Rüsselsheim am Main, Germany
Gebundene Ausgabe. Condition: Sehr gut. 416 Seiten ex Library Book aus einer wissenschaftlichen Bibliothek Sprache: Englisch Gewicht in Gramm: 1418. Seller Inventory # 251064